Tiotropium respimat increases the risk of mortality: Con

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 590-593

  Bateman, Eric D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVICE SAFETY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRY POWDER INHALER; EDITORIAL; HUMAN; INHALER; MAXIMUM PLASMA CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOFT MIST INHALER; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84883507707     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00042213     Document Type: Editorial

References (22)

1. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Eng J Med 2008; 359: 1543-1554.
2. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840. (Pubitemid 38807355)
3. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178. (Pubitemid 41324392)
4. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-955.
5. Van Noord JA, Cornelissen PJG, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mis Inhaler or HandHaler in COPD patients. Respir Med 2009; 103: 22-29.
6. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mg via Respimat and 18 μg via HandiHaler®; efficacy and safety in Japanese COPD patients. Respir Med 2010; 104: 228-236.
7. Bateman ED, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5: 197-208.
8. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010; 104: 1460-1472.
9. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010; 363: 1097-1099.
10. ClinicalTrials.gov. Comparison of Tiotropium in the HandiHaler versus the Respimat in Chronic Obstructive Pulmonary Disease. http://www.clinicaltrials. gov/ct2/show/study/NCT01126437
11. US National Institutes of Health. ClinicalTrials.gov. Tiotropium Respimat pharmacokinetic study in COPD. 2010. www.clinicaltrials.gov/ct2/show/results/ NCT01222533
12. Ram FS. Spiriva (Respimat) increases mortality by 52% in patients with COPD: time to take action. N Z Med J 2011; 124: 117-118.
13. Beasley R, Singh S, Loke YK, et al. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 2012; 345: e7390.
14. Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Int Med 1989; 149: 2414-2420. (Pubitemid 19283196)
15. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-1450.
16. Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med 2010; 10: 50.
17. Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013; 68: 114-116.
18. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trials. BMJ 2011; 342: d3215.
19. Kesten S, Jara M, Wentworth C. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695-1703. (Pubitemid 46033421)
20. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medication in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68: 48-56.
21. Jenkins CR, Beasley R. Tiotropium Respimat increases risk of mortality. Thorax 2013; 68: 5-7.
22. Abrahams R, Moroni-Zentgraf P, Ramsdell J, et al. Safety and efficacy of the once-daily anticholinergic BEA2180 compared to tiotropium in patients with COPD. Respir Med 2013; 107: 854-862.